Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
KOOL's Cash to Debt is ranked higher than
86% of the 479 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. KOOL: No Debt )
KOOL' s 10-Year Cash to Debt Range
Min: 0.87   Max: No Debt
Current: No Debt

Equity to Asset 0.77
KOOL's Equity to Asset is ranked higher than
83% of the 449 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. KOOL: 0.77 )
KOOL' s 10-Year Equity to Asset Range
Min: 0.45   Max: 0.91
Current: 0.77

0.45
0.91
Interest Coverage No Debt
KOOL's Interest Coverage is ranked higher than
78% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 231.38 vs. KOOL: No Debt )
KOOL' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: -1.47
M-Score: 79.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -79.01
KOOL's Operating margin (%) is ranked higher than
54% of the 463 Companies
in the Global Medical Devices industry.

( Industry Median: 6.11 vs. KOOL: -79.01 )
KOOL' s 10-Year Operating margin (%) Range
Min: -211.11   Max: -9.09
Current: -79.01

-211.11
-9.09
Net-margin (%) -76.65
KOOL's Net-margin (%) is ranked higher than
55% of the 463 Companies
in the Global Medical Devices industry.

( Industry Median: 4.39 vs. KOOL: -76.65 )
KOOL' s 10-Year Net-margin (%) Range
Min: -213.33   Max: -3.03
Current: -76.65

-213.33
-3.03
ROE (%) -33.19
KOOL's ROE (%) is ranked higher than
56% of the 448 Companies
in the Global Medical Devices industry.

( Industry Median: 5.76 vs. KOOL: -33.19 )
KOOL' s 10-Year ROE (%) Range
Min: -141.18   Max: -13.56
Current: -33.19

-141.18
-13.56
ROA (%) -25.87
KOOL's ROA (%) is ranked higher than
58% of the 481 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. KOOL: -25.87 )
KOOL' s 10-Year ROA (%) Range
Min: -106.67   Max: -10.6
Current: -25.87

-106.67
-10.6
ROC (Joel Greenblatt) (%) -182.43
KOOL's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 480 Companies
in the Global Medical Devices industry.

( Industry Median: 9.33 vs. KOOL: -182.43 )
KOOL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -231.71   Max: -36.5
Current: -182.43

-231.71
-36.5
Revenue Growth (3Y)(%) -25.20
KOOL's Revenue Growth (3Y)(%) is ranked higher than
51% of the 350 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. KOOL: -25.20 )
KOOL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -25.2   Max: 20.4
Current: -25.2

-25.2
20.4
EBITDA Growth (3Y)(%) 27.30
KOOL's EBITDA Growth (3Y)(%) is ranked higher than
92% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. KOOL: 27.30 )
KOOL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -38.9   Max: 270.2
Current: 27.3

-38.9
270.2
EPS Growth (3Y)(%) 28.40
KOOL's EPS Growth (3Y)(%) is ranked higher than
90% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. KOOL: 28.40 )
KOOL' s 10-Year EPS Growth (3Y)(%) Range
Min: -36.4   Max: 278
Current: 28.4

-36.4
278
» KOOL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

KOOL Guru Trades in Q2 2013

Jim Simons 191,000 sh (+2.85%)
» More
Q3 2013

KOOL Guru Trades in Q3 2013

Jim Simons 222,000 sh (+16.23%)
» More
Q4 2013

KOOL Guru Trades in Q4 2013

Jim Simons 187,700 sh (-15.45%)
» More
Q1 2014

KOOL Guru Trades in Q1 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KOOL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.80
KOOL's P/B is ranked higher than
97% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 4.25 vs. KOOL: 0.80 )
KOOL' s 10-Year P/B Range
Min: 0.62   Max: 20.7
Current: 0.8

0.62
20.7
P/S 1.60
KOOL's P/S is ranked higher than
83% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 3.71 vs. KOOL: 1.60 )
KOOL' s 10-Year P/S Range
Min: 0.56   Max: 26.07
Current: 1.6

0.56
26.07
EV-to-EBIT -2.28
KOOL's EV-to-EBIT is ranked lower than
53% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 75.34 vs. KOOL: -2.28 )
KOOL' s 10-Year EV-to-EBIT Range
Min: -49.4   Max: 0.5
Current: -2.28

-49.4
0.5
Current Ratio 3.78
KOOL's Current Ratio is ranked higher than
80% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 2.48 vs. KOOL: 3.78 )
KOOL' s 10-Year Current Ratio Range
Min: 1.52   Max: 16.85
Current: 3.78

1.52
16.85
Quick Ratio 2.74
KOOL's Quick Ratio is ranked higher than
78% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 1.88 vs. KOOL: 2.74 )
KOOL' s 10-Year Quick Ratio Range
Min: 0.86   Max: 15.88
Current: 2.74

0.86
15.88
Days Inventory 174.47
KOOL's Days Inventory is ranked higher than
67% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 165.69 vs. KOOL: 174.47 )
KOOL' s 10-Year Days Inventory Range
Min: 114.21   Max: 353.59
Current: 174.47

114.21
353.59
Days Sales Outstanding 103.14
KOOL's Days Sales Outstanding is ranked higher than
63% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 79.24 vs. KOOL: 103.14 )
KOOL' s 10-Year Days Sales Outstanding Range
Min: 54.35   Max: 124.63
Current: 103.14

54.35
124.63

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 10.10
KOOL's Price/Net Current Asset Value is ranked higher than
93% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. KOOL: 10.10 )
KOOL' s 10-Year Price/Net Current Asset Value Range
Min: 0.7   Max: 72.73
Current: 10.1

0.7
72.73
Price/Tangible Book 4.80
KOOL's Price/Tangible Book is ranked higher than
74% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 7.75 vs. KOOL: 4.80 )
KOOL' s 10-Year Price/Tangible Book Range
Min: 0.64   Max: 36.11
Current: 4.8

0.64
36.11
Price/Median PS Value 0.70
KOOL's Price/Median PS Value is ranked higher than
91% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 1.47 vs. KOOL: 0.70 )
KOOL' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 13.17
Current: 0.7

0.3
13.17
Earnings Yield (Greenblatt) -43.60
KOOL's Earnings Yield (Greenblatt) is ranked lower than
60% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. KOOL: -43.60 )
KOOL' s 10-Year Earnings Yield (Greenblatt) Range
Min: -46.5   Max: 2261.4
Current: -43.6

-46.5
2261.4

Analyst Estimate

Jun15 Jun16 Jun17 Jun18
Revenue(Mil) 17 19 77 151
EPS($) -0.39 -0.34 -0.02 0.32
EPS without NRI($) -0.39 -0.34 -0.02 0.32

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:THRA.Germany,
Cesca Therapeutics Inc., formerly known as ThermoGenesis Corp, founded in 1986 in California. The Company is engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine. It serves patients, physicians and partners through cellular therapeutics, medical/diagnostic device development and commercialization, and cell manufacturing and banking markets. The Company offers SurgWerks, a therapeutic technology platform, in various stages of clinical trials as a potential treatment for acute myocardial infarction, critical limb ischemia, and orthopedic injuries. It also offers CellWerks, an indication-specific device/protocol program for select applications in umbilical cord blood banking, bone marrow transplantation, and regenmed bioprocess markets. The Company complies under a variety of Good practices concerning operation of clinical cell manufacturing, processing, testing, and storage facilities, as well as patient safety, quality laboratory documentation, and quality cell processing and handling. It supports production of personalized medicine prescriptions and large scale batch processes. The Company has the ability to support various device prototyping and validation, typically required in a combination product. Its clinical research organization is specialized, in-hospital and cell therapy CRO.
» More Articles for KOOL

Headlines

Articles On GuruFocus.com
comment on KOOL Dec 01 2011 
comment on KOOL Aug 27 2011 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 11 2011 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 09 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares Sep 28 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares May 13 2009 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
Delphi's autonomous car proof of concept: driving itself across the U.S. Mar 20 2015
CESCA THERAPEUTICS TO PRESENT AT 3RD ANNUAL REGEN MED INVESTOR DAY Mar 19 2015
Cesca Therapeutics to Present at 3rd Annual Regen Med Investor Day Mar 19 2015
MicroCap Review Magazine Winter/Spring 2015 Issue Now Available Mar 04 2015
CESCA THERAPEUTICS INC. Financials Mar 03 2015
CESCA THERAPEUTICS INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Feb 27 2015
Cesca Therapeutics Receives Notice of Non-Compliance With Nasdaq Listing Rule Feb 27 2015
CESCA THERAPEUTICS INC. Files SEC form 8-K, Financial Statements and Exhibits Feb 17 2015
CESCA THERAPEUTICS REPORTS SECOND QUARTER FISCAL 2015 RESULTS Feb 12 2015
CESCA THERAPEUTICS TO ANNOUNCE SECOND QUARTER FISCAL 2015 RESULTS ON FEBRUARY 12, 2015 Feb 12 2015
CESCA THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 12 2015
Cesca Therapeutics Announces Approval of Its MarrowXpress(TM) System in India Feb 11 2015
Cesca Therapeutics to Announce Second Quarter Fiscal 2015 Results on February 12, 2015 Feb 11 2015
CESCA THERAPEUTICS TO PRESENT AT 17TH ANNUAL BIO CEO & INVESTOR CONFERENCE Feb 09 2015
Cesca Therapeutics to Present at 17th Annual BIO CEO & Investor Conference Feb 09 2015
3 technologies to watch from the Consumer Electronics Show Jan 21 2015
Why Ford is leading the way with innovation that goes beyond vehicles Jan 20 2015
Technology's future looks better than ever for business opportunities Jan 14 2015
Automotive innovation takes center stage at CES Jan 13 2015
At the Silicon Valley International Auto Show, check out car-tech that's within reach (slideshow) Jan 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK